Answers are grounded in this paper and cite their sources.
The classification of CNS tumors according to objective, reproducible molecular genetic alterations, provides greater opportunity for neurologists to offer individualized treatment options, enroll homogenous patient populations into clinical trials, and ultimately discover novel therapeutics.
No takes yet. Share an insight, caveat, or question.
Jamshidi et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: